Showing results (211-220 of 241) with videos related to

Sort By:
Pageof 25
Blood|October 29, 2014
Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3Emma M Haapaniemi, Meri Kaustio, Hanna L M Rajala, et al.
Acta Oncologica (Stockholm, Sweden)|March 11, 2026
Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU® cohort studyAnton Barchuk, Cesar Barboza, Julieta Politi, et al.
Haematologica|October 5, 2019
A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cellsSofia von Palffy, Niklas Landberg, Carl Sandén, et al.
Therapeutic Drug Monitoring|December 24, 2015
In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid LeukemiaKarin Skoglund, Johan Richter, Ulla Olsson-Strömberg, et al.
Hemasphere|August 5, 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 TrialHartmut Döhner, Argiris Symeonidis, Dries Deeren, et al.
The New England Journal of Medicine|May 18, 2012
Somatic STAT3 mutations in large granular lymphocytic leukemiaHanna L M Koskela, Samuli Eldfors, Pekka Ellonen, et al.
The New England Journal of Medicine|August 14, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaCourtney D DiNardo, Brian A Jonas, Vinod Pullarkat, et al.
Hemasphere|June 8, 2026
Prognostic value of measurable residual disease in high-risk MDS after intensive chemotherapy in HOVON-SAKK studiesCoen R Veenstra, Lok Lam Ngai, Patrycja Gradowska, et al.
Blood Advances|January 4, 2018
Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cellsMia Eriksson, Pablo Peña-Martínez, Ramprasad Ramakrishnan, et al.
Journal of Cancer Research and Clinical Oncology|March 25, 2017
Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemiaHanna L M Rajala, Mohamed El Missiry, Anniina Ruusila, et al.
Pageof 25